Tags

Type your tag names separated by a space and hit enter

[Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
Minerva Med. 1992 Nov; 83(11):739-44.MM

Abstract

One of the most appealing current pathogenetic concepts is that progressive systemic sclerosis (PSS) is a reaction to repeated episodes of endothelial cell injury. Injury of small arteries and capillary endothelium initiates reactions which involve increased permeability of the vessels, platelet adherence, myointimal cell proliferation, luminal narrowing and heightened sensitivity of the vessel wall. Clinical evidence of the vessel damage is Raynaud's phenomenon, involving both skin and viscera. The Authors evaluated the effects of iloprost on Raynaud's phenomenon in patients with PSS. This drug provides prolonged vasodilation, reduces platelet aggregation and promotes endothelial lining function repair. This last pattern is of primary importance because it may stop the vicious circle: endothelial injury-platelet hyperaggregation-microangiospasm. Five females were recruited, aged 41-66 years, suffering from well-documented (ARA criteria) PSS, associated with typical Raynaud's phenomenon. The trial provided for intravenous infusion of iloprost at a rate of 1-2 ng/kg/min. First treatment consisted of six-hour infusions on six successive days. After this first treatment, weekly infusions during the winter months were carried on. Drug effectiveness was considered through subjective and objective parameters. All patients showed prominent reduction of number, duration and severity of attacks of Raynaud's phenomenon, improvement of prehensile strength, healing of finger ulcerations and improvement or normalization of digital photoplethysmography. So far, the treatment has been prolonged for years in our patients and still goes on. The side effects of iloprost (headache, flushing, nausea) have been very poor. Therefore, iloprost proved to be a valid drug in the management of Raynaud's phenomenon in patients with PSS, but the inconvenience of intravenous administration may limit its routine use.

Authors+Show Affiliations

Istituto di Patologia Speciale Medica, Università degli Studi di Bologna.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
English Abstract
Journal Article

Language

ita

PubMed ID

1281297

Citation

Cordioli, E, et al. "[Effects of Long-term Iloprost Therapy On Raynaud's Phenomenon in Progressive Systemic Sclerosis]." Minerva Medica, vol. 83, no. 11, 1992, pp. 739-44.
Cordioli E, Virgilio S, Ghirardi R, et al. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis]. Minerva Med. 1992;83(11):739-44.
Cordioli, E., Virgilio, S., Ghirardi, R., & Martinelli, M. (1992). [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis]. Minerva Medica, 83(11), 739-44.
Cordioli E, et al. [Effects of Long-term Iloprost Therapy On Raynaud's Phenomenon in Progressive Systemic Sclerosis]. Minerva Med. 1992;83(11):739-44. PubMed PMID: 1281297.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis]. AU - Cordioli,E, AU - Virgilio,S, AU - Ghirardi,R, AU - Martinelli,M, PY - 1992/11/1/pubmed PY - 1992/11/1/medline PY - 1992/11/1/entrez SP - 739 EP - 44 JF - Minerva medica JO - Minerva Med. VL - 83 IS - 11 N2 - One of the most appealing current pathogenetic concepts is that progressive systemic sclerosis (PSS) is a reaction to repeated episodes of endothelial cell injury. Injury of small arteries and capillary endothelium initiates reactions which involve increased permeability of the vessels, platelet adherence, myointimal cell proliferation, luminal narrowing and heightened sensitivity of the vessel wall. Clinical evidence of the vessel damage is Raynaud's phenomenon, involving both skin and viscera. The Authors evaluated the effects of iloprost on Raynaud's phenomenon in patients with PSS. This drug provides prolonged vasodilation, reduces platelet aggregation and promotes endothelial lining function repair. This last pattern is of primary importance because it may stop the vicious circle: endothelial injury-platelet hyperaggregation-microangiospasm. Five females were recruited, aged 41-66 years, suffering from well-documented (ARA criteria) PSS, associated with typical Raynaud's phenomenon. The trial provided for intravenous infusion of iloprost at a rate of 1-2 ng/kg/min. First treatment consisted of six-hour infusions on six successive days. After this first treatment, weekly infusions during the winter months were carried on. Drug effectiveness was considered through subjective and objective parameters. All patients showed prominent reduction of number, duration and severity of attacks of Raynaud's phenomenon, improvement of prehensile strength, healing of finger ulcerations and improvement or normalization of digital photoplethysmography. So far, the treatment has been prolonged for years in our patients and still goes on. The side effects of iloprost (headache, flushing, nausea) have been very poor. Therefore, iloprost proved to be a valid drug in the management of Raynaud's phenomenon in patients with PSS, but the inconvenience of intravenous administration may limit its routine use. SN - 0026-4806 UR - https://www.unboundmedicine.com/medline/citation/1281297/[Effects_of_long_term_iloprost_therapy_on_Raynaud's_phenomenon_in_progressive_systemic_sclerosis]_ L2 - http://www.diseaseinfosearch.org/result/2275 DB - PRIME DP - Unbound Medicine ER -